for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

GlaxoSmithKline plc

GSK.L

Latest Trade

1,671.60GBp

Change

13.80(+0.83%)

Volume

16,764,882

Today's Range

1,646.40

 - 

1,678.20

52 Week Range

1,408.80

 - 

1,767.00

As of on the London Stock Exchange (LON) ∙ Minimum 15 minute delay

Pricing

Previous Close
1,657.80
Open
1,649.20
Volume
16,764,882
3M AVG Volume
138.98
Today's High
1,678.20
Today's Low
1,646.40
52 Week High
1,767.00
52 Week Low
1,408.80
Shares Out (MIL)
4,988.55
Market Cap (MIL)
83,388.60
Forward P/E
14.33
Dividend (Yield %)
--

Next Event

GlaxoSmithKline PLC Vaccines Investor Event

Latest Developments

More

GSK Gets Positive CHMP Opinion For Intravenous Benlysta In Children With Lupus Aged 5 & Above

Microsoft - Charles Noski And Helmut Panke To Retire From Board - SEC Filing

FDA Panel Says Benefits Of GlaxoSmithKline's OTC Nicotine Oral Spray Outweigh Risks

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About GlaxoSmithKline plc

GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.

Industry

Biotechnology & Drugs

Contact Info

G S K House, 980 Great West Road

+44.20.80475000

https://www.gsk.com/

Executive Leadership

Jonathan Richard Symonds

Independent Non-Executive Chairman of the Board

Emma N. Walmsley

Chief Executive Officer, Executive Director

Iain James Mackay

Chief Financial Officer, Executive Director

Roger G. Connor

President - Vaccines

Brian McNamara

Chief Executive Officer - GSK Consumer Healthcare

Key Stats

2.60 mean rating - 25 analysts
Sell
Hold
Buy
Revenue (MM, GBP)

2016

27.9K

2017

30.2K

2018

30.8K

2019(E)

32.6K
EPS (GBp)

2016

102.400

2017

111.800

2018

119.400

2019(E)

116.643
Price To Earnings (TTM)
18.29
Price To Sales (TTM)
2.63
Price To Book (MRQ)
23.07
Price To Cash Flow (TTM)
10.28
Total Debt To Equity (MRQ)
925.84
LT Debt To Equity (MRQ)
645.07
Return on Investment (TTM)
12.65
Return on Equity (TTM)
8.20

Latest News

Microsoft nominates GSK CEO Walmsley to board

Microsoft Corp said on Thursday it has nominated GlaxoSmithKline Plc Chief Executive Officer Emma Walmsley to its board of directors.

GSK's over-the-counter nicotine oral spray gets FDA panel backing

An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc's over-the-counter nicotine oral spray that aims to help smokers quit their addiction.

FDA panel recommends GSK's over-the-counter nicotine oral spray

An independent expert panel to the U.S. Food and Drug Administration on Wednesday recommended approval of GlaxoSmithKline Plc's over-the-counter nicotine oral spray that aims to help smokers quit their nicotine addiction.

UPDATE 2-AstraZeneca respiratory business gets boost from 3-drug inhaler results

* Fasenra gets U.S. FDA orphan drug status (Adds details on Breztri data)

GSK builds oncology pipeline as drug shown to help myeloma patients

GlaxoSmithKline said an experimental multiple myeloma treatment has shown a meaningful response in patients that have run out of three previous treatment options, in a boost for the British drugmaker's cancer drug business.

GSK's long acting HIV injection gets boost from study

GlaxoSmithKline's experimental HIV injection is as effective when given every other month as monthly, according to a study, a convenience that could help the British drugmaker in its battle against a rival drug from Gilead Sciences.GSK's two-drug injection was as effective...

GSK new HIV two-drug injection meets main goal in late-stage study

British drugmaker GlaxoSmithKline Plc said on Thursday its long-lasting two-drug regimen to treat HIV met the main goal of a late-stage study.

AstraZeneca scores win in race to treat ovarian cancer

AstraZeneca has made further headway in the race with larger competitor GlaxoSmithKline's to use a promising new class of drugs to treat ovarian cancer.

GSK ends development of Ebola vaccine, hands work to U.S. institute

British drugmaker GlaxoSmithKline <GSK.L> is giving up its work on developing three potential vaccines against the deadly Ebola and Marburg viruses, despite an ongoing Ebola outbreak in Democratic Republic of Congo.

GSK hands work on potential Ebola vaccines to U.S. institute

British drugmaker GlaxoSmithKline is handing over all its development work on three potential vaccines against the deadly Ebola and Marburg viruses despite an ongoing Ebola outbreak in Democratic Republic of Congo.

GSK raises 2019 earnings expectations after standout quarter for Shingrix

GlaxoSmithKline <GSK.L> beat second quarter profit expectations with the help of strong demand for its shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit this year than originally anticipated.

REFILE-UPDATE 1-GSK predicts smaller fall in 2019 profit after standout quarter for Shingrix

GlaxoSmithKline Plc on Wednesday forecast a smaller than previously estimated fall in full-year profit after the British drugmaker beat profit consensus for the second quarter due to demand for its fast-growing Shingles vaccine.

GSK forecasts smaller hit to FY profit after Q2 beat

GlaxoSmithKline Plc on Wednesday forecast a smaller-than estimated fall in full-year profit after the British drugmaker beat profit consensus for the second quarter due to demand for its fast-growing Shingles vaccine.

Drugmaker GSK ends chairman search with HSBC's Symonds

GlaxoSmithKline <GSK.L> has appointed HSBC's <HSBA.L> Jonathan Symonds to succeed Philip Hampton as non-executive chairman, ending a six month search as the drugmaker prepares to split its businesses into two.

GSK names HSBC's Symonds as non-exec chairman

Drugmaker GlaxoSmithKline Plc on Wednesday named HSBC's Jonathan Symonds as non-executive chairman to replace Philip Hampton. (Reporting by Pushkala Aripaka in Bengaluru; editing by Jason Neely)

Swiss agree to extradite Chinese scientist to U.S. on theft charges

Switzerland has agreed to extradite a Chinese researcher to the United States where prosecutors have charged him with helping his scientist sister steal secrets allegedly worth $550 million from British drugmaker GlaxoSmithKline.

GSK's two-drug HIV Dovato treatment meets main goal in study

(This July 10 story corrects to show patients switched from Gilead's Descovy, not Gilead's Vemlidy, in fifth paragraph)

CORRECTED-UPDATE 1-GSK's Dovato suppresses AIDS virus at same levels of 3-drug regimen (July 10)

GlaxoSmithKline Plc's two-drug HIV regimen Dovato was successful in suppressing the AIDS-causing virus in patients over 48 weeks at the same level of a previous three-drug treatment in a late-stage study, the drugmaker said on Wednesday.

GSK drug helps ovarian cancer patients live longer in late-stage study

GlaxoSmithKline Plc's cancer treatment Zejula met the main goal of helping patients with ovarian cancer live longer without their disease worsening in a late-stage study, the company said on Monday.

GSK's ovarian cancer treatment meets main goal in late-stage study

GlaxoSmithKline said on Monday a late-stage study testing Zejula as a maintenance therapy in patients with first-line ovarian cancer showed positive headline results.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up